Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Revenue: 2020-2025

Historic Revenue for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $74.4 million.

  • Xeris Biopharma Holdings' Revenue rose 37.06% to $74.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.1 million, marking a year-over-year increase of 42.05%. This contributed to the annual value of $203.1 million for FY2024, which is 23.89% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Revenue stood at $74.4 million for Q3 2025, which was up 3.97% from $71.5 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Revenue ranged from a high of $74.4 million in Q3 2025 and a low of $8.2 million during Q1 2021.
  • Moreover, its 3-year median value for Revenue was $48.3 million (2023), whereas its average is $52.1 million.
  • Data for Xeris Biopharma Holdings' Revenue shows a peak YoY spiked of 192.15% (in 2021) over the last 5 years.
  • Over the past 5 years, Xeris Biopharma Holdings' Revenue (Quarterly) stood at $21.4 million in 2021, then spiked by 54.67% to $33.1 million in 2022, then surged by 33.93% to $44.4 million in 2023, then surged by 35.39% to $60.1 million in 2024, then surged by 37.06% to $74.4 million in 2025.
  • Its Revenue stands at $74.4 million for Q3 2025, versus $71.5 million for Q2 2025 and $60.1 million for Q1 2025.